Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis

Area of Science:

• Psychiatry and Pharmaceutical Sciences
• Pharmacometrics and Statistical Modeling

Background:

• Dose-response relationships for psychotropic medications can be challenging to ascertain from individual clinical trials, especially those with flexible dosing.
• Characterizing these relationships is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

• To perform a pharmacometric analysis to characterize the dose-response profile of lurasidone in patients diagnosed with bipolar depression.

Main Methods:

• Utilized pooled data from two randomized, double-blind, placebo-controlled, flexible-dose studies in bipolar depression patients.
• Included 5245 Montgomery-Åsberg Depression Rating Scale (MADRS) observations from 825 patients treated with lurasidone or placebo, with or without lithium/valproate.

Main Results:

• A linear model effectively described lurasidone's dose-response, indicating a significant positive correlation between dose and therapeutic effect.
• Lurasidone demonstrated a net improvement of 6.0 points on the MADRS score per 100 mg dose after 6 weeks.
• Covariate analyses revealed no necessary dose adjustments for age or concomitant lithium/valproate use.

Conclusions:

• Population dose-response modeling suggests higher lurasidone doses yield greater therapeutic benefits in bipolar depression.
• The observed linear dose-response was consistent for both lurasidone monotherapy and adjunctive use.